Kim Henderson
Mayo Clinic
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kim Henderson.
Cancer Research | 2007
Wee J. Chng; Shaji Kumar; Scott VanWier; Greg J. Ahmann; Tammy Price-Troska; Kim Henderson; Tae Hoon Chung; Seungchan Kim; George Mulligan; Barbara M. Bryant; John D. Carpten; Morie A. Gertz; S. Vincent Rajkumar; Martha Q. Lacy; Angela Dispenzieri; Robert A. Kyle; Philip R. Greipp; P. Leif Bergsagel; Rafael Fonseca
Hyperdiploid multiple myeloma (H-MM) is the most common form of myeloma. In this gene expression profiling study, we show that H-MM is defined by a protein biosynthesis signature that is primarily driven by a gene dosage mechanism as a result of trisomic chromosomes. Within H-MM, four independently validated patient clusters overexpressing nonoverlapping sets of genes that form cognate pathways/networks that have potential biological importance in multiple myeloma were identified. One prominent cluster, cluster 1, is characterized by high expression of cancer testis antigen and proliferation-associated genes. Tumors from these patients were more proliferative than tumors in other clusters (median plasma cell labeling index, 3.8; P < 0.05). Another cluster, cluster 3, is characterized by genes involved in tumor necrosis factor/nuclear factor-kappaB signaling and antiapoptosis. These patients have better response to bortezomib as compared with patients within other clusters (70% versus 29%; P = 0.02). Furthermore, for a group of patients generally thought to have better prognosis, a cluster of patients with short survival (cluster 1; median survival, 27 months) could be identified. This analysis illustrates the heterogeneity within H-MM and the importance of defining specific cytogenetic prognostic factors. Furthermore, the signatures that defined these clusters may provide a basis for tailoring treatment to individual patients.
Cancer Research | 2013
Angela Baker; Esteban Braggio; Susana Jacobus; Sungwon Jung; Dirk R. Larson; Terry M. Therneau; Angela Dispenzieri; Scott Van Wier; Gregory J. Ahmann; Joan Levy; Louise M. Perkins; Seungchan Kim; Kim Henderson; David H. Vesole; S. Vincent Rajkumar; Dianne Jelinek; John D. Carpten; Rafael Fonseca
The plasma cell malignancy Multiple Myeloma (MM) is a rare but deadly form of cancer with 5 year survival rates of ∼30%. Epidemiological studies have suggested that MM exacts an especially heavy burden on African American (AA) patients. We examined a multi-ethnic cohort of MM tumors to assess potential differences in the frequency of molecular events in tumors derived from either African American (AA) or European American (EA) patients. The frequency of 14q32 translocation breakpoints at the IgH locus was compared among a series of data from 115 AA MM patients from three studies and EA MM from the Eastern Cooperative Oncology Group (ECOG). In addition, we analyzed matching genome-wide copy number and transcriptional data among 45 AA MM tumors and 196 EA MM tumors to determine differences in the frequency of molecular events in tumors from these populations. No differences were found for specific translocation subtypes; however, we detected a statistically significant difference in the overall frequency of IgH translocations between the two groups, which occurred more frequently in EA patients (52% vs. 40%; p = 0.032). When assessing genomic copy number events previously shown to be associated with poor outcome in MM, frequencies of alterations were not significant after correcting for multiple testing. Furthermore, there was not a significant difference in the association of high-risk disease using expression profiling. Our study represents the first comprehensive assessment of the frequency and distribution of molecular alterations in MM tumors from both AA and EA patients and could help shed light on possible biological features associated with population differences in incidence and outcome in MM. Citation Format: Angela S. Baker, Esteban Braggio, Susana Jacobus, Sungwon Jung, Dirk Larson, Terry Therneau, Angela Dispenzieri, Scott A. Van Wier, Gregory Ahmann, Joan Levy, Louise Perkins, Seungchan Kim, Kim Henderson, David Vesole, S. Vincent Rajkumar, Dianne F. Jelinek, John Carpten, Rafael Fonseca. Characterization of myeloma tumors from a multi-ethnic cohort using cytogenetics and genomic analysis. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2021. doi:10.1158/1538-7445.AM2013-2021
Cancer Research | 2012
Angela Baker; Esteban Braggio; Suzanna Jacobus; Jonathan J. Keats; Sungwon Jung; Dirk R. Larson; Terry M. Therneau; Angela Dispenzieri; Scott A. Van Weir; Gregory J. Ahmann; Kim Henderson; S. Vincent Rajkumar; Dianne Jelinek; Seungchan Kim; John D. Carpten; Rafael Fonseca
Previous epidemiological studies have suggested that African Americans (AA) are twice as likely to be diagnosed with and to die from Multiple Myeloma (MM) as compared to European Americans (EA). In recent years, however, mortality rates have become more comparable between these groups. Although socioeconomic factors could play a major role to this potential disparity, biological factors may also be responsible for influencing these differences in either incidence and/or mortality. Here we examined a multi-ethnic cohort of MM tumors to assess potential differences in the frequency of molecular events in tumors derived from either African American (AA) or European American (EA) patients. First, we compared the frequency of 14q32 translocation breakpoints at the IgH locus among a series of data from 115 AA MM patients from three studies and EA MM from the Eastern Cooperative Oncology Group (ECOG). Furthermore, we analyzed matching genome-wide copy number and transcriptional data among 47 AA MM tumors and 196 EA MM tumors to determine differences in the frequency of molecular events in tumors from these populations. Univariate analyses were conducted using the Fisher9s Exact Test and p-values were calculated to measure statistical significance. We observed statistically significant differences in the frequency of IgH translocations and somatic copy number alterations. Although we did not detect differences for specific translocation subtypes, we saw a statistically significant difference in the overall frequency of IgH translocations between the two groups, which occurred more frequently in EA patients (p = 0.032). When assessing genomic copy number events previously shown to be associated with poor outcome in MM, chromosome 13 monosomy was more frequent in hyperdiploid MM from AA patients and significant after correcting for multiple testing using the Bonferoni correction method (p = 0.001). Moreover, when using the Benjamini-Hochberg multiple testing correction method, chromosome 13 monosomy remained significantly different among hyperdiploid AA patients (p = 0.0121). Chromosome 1q amplification was also significant among hyperdiploid tumors from EA patients when using this correction method (p = 0.036). No differences in the frequency of hyperdiploid status or gene expression-based subtypes were detected when comparing tumors from AA and EA patients. Our study represents the first comprehensive assessment of the frequency and distribution of molecular alterations in MM tumors from both AA and EA patients and could help shed light on possible biological features associated with population differences in incidence and outcome in MM. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5064. doi:1538-7445.AM2012-5064
Blood | 2005
Wee Joo Chng; Scott Van Wier; Gregory J. Ahmann; Jerry M. Winkler; Syed M. Jalal; Peter Leif Bergsagel; Marta Chesi; Mike C. Trendle; Martin M. Oken; Emily A. Blood; Kim Henderson; Rafael Santana-Davila; Robert A. Kyle; Morie A. Gertz; Martha Q. Lacy; Angela Dispenzieri; Philip R. Greipp; Rafael Fonseca
Blood | 2006
Wee J. Chng; Greg J. Ahmann; Kim Henderson; Rafael Santana-Davila; Philip R. Greipp; Morie A. Gertz; Martha Q. Lacy; Angela Dispenzieri; Shaji Kumar; S. Vincent Rajkumar; John A. Lust; Robert A. Kyle; Steven R. Zeldenrust; Suzanne R. Hayman; Rafael Fonseca
Blood | 2008
Soledad Molnar; Victor J Jimenez Zepeda; Scott Van Wier; Esteban Braggio; Jonathan J. Keats; Michael Kuehl; Tammy Price-Troska; Greg J. Ahmann; Rachel Rempel; Kim Henderson; S. Vincent Rajkumar; Philip R. Greipp; Daniel Auclair; John Carpten; Angela Baker; Keith Stewart; P. Leif Bergsagel; Wee Joo Chng; Rafael Fonseca
Blood | 2005
Rafael Fonseca; Scott Van Wier; Wee Joo Chng; Rhett P. Ketterling; Martha Q. Lacy; Angela Dispenzieri; Peter Leif Bergsagel; S. Vincent Rajkumar; Philip R. Greipp; Mark R. Litzow; Shaji Kumar; Natalia Gonzalez-Paz; Kim Henderson; Gregory J. Ahmann; Morie A. Gertz
Blood | 2004
Morie A. Gertz; Martha Q. Lacy; Angela Dispenzieri; Philip R. Greipp; Mark R. Litzow; Kim Henderson; Scott Van Wier; Gregory J. Ahmann; Rafael Fonseca
Blood | 2007
Wee J. Chng; Marta Chesi; Tammy Price-Troska; Greg J. Ahmann; Kim Henderson; Philip R. Greipp; Robert A. Kyle; S. Vincent Rajkumar; Morie A. Gertz; Rafael Fonseca; P. Leif Bergsagel
Archive | 2013
Rafael Fonseca; Robert A. Kyle; Morie A. Gertz; Martha Q. Lacy; Angela Dispenzieri; Marta Chesi; Mike C. Trendle; Martin M. Oken; Kim Henderson; Joo Chng; Scott Van Wier; Gregory J. Ahmann; Jerry M. Winkler; Syed M. Jalal; Peter Leif